Audrito et al. extensively demonstrated the driver role of the NAMPT/NAD axis in the acquisition of resistance to BRAF inhibitors: (i) NAMPT appeared to be the master regulator of NAD biosynthesis in resistant melanoma cells, a key element involved in metabolic reprogramming [45,186]; (ii) melanoma patients, including those resistant to BRAF inhibitors, showed increased tissue and serum expression of NAMPT as compared to healthy controls or to patients with localized disease. The gene discussed is NAMPT; the disease is melanoma.